Toumaz Technology Successfully Delivers Technology Platform for Collaborative EU-Funded DIAdvisor Clinical Trial

Toumaz Holdings announced that its wholly-owned subsidiary Toumaz Technology Limited has successfully completed the timely delivery of the hardware, software and sensors that are being used to capture large-scale data in the first phase of DIAdvisor’s clinical trial. DIAdvisor is a collaborative research project aiming to develop a personal blood glucose predictor and treatment advisor for diabetes patients.

DIAdvisor (www.diadvisor.eu) is a large-scale integrating project (IP) aiming at the development of a prediction-based tool which uses past and easily available information to optimise the therapy of type I and developed type II diabetes. DIAdvisor will allow patients to actively and accurately predict their short-term blood glucose outlook at any time by analysing data retrieved from glucose measurements, insulin delivery data and specific patient parameters.

The key data, captured by non-intrusive body-worn wireless monitors including those based on Toumaz Technology’s breakthrough Sensium platform, will be used to create physiological mathematical modelling, control and prediction algorithms. The resulting analysis and prediction information will be wirelessly transmitted to a healthcare provider advisory service, with recommended action and treatment advice presented to the patient via a handheld mobile device such as a personal digital assistant (PDA).

The first year of the project oversaw the implementation of a large-scale data-acquisition clinical trial involving 90 patients across three sites in Europe; France, Italy and Czech Republic.

The collaborative DIAdvisor project received a €7.1 million European Community Grant in April 2008 and the large-scale four-year research and development project is being coordinated by Novo Nordisk A/S, a world leader in diabetes care. It will be delivered by a consortium of 13 medical, industrial and academic partners, including the European Division of the International Diabetes Federation.

“The development of the DIAdvisor personal blood glucose predictor and treatment advisor has the potential to revolutionize the therapy of millions of diabetes sufferers in Europe and worldwide, minimizing the occurrence of diabetic complications and reducing healthcare costs,” said Dr. Alison Burdett, director of technology for Toumaz Technology. “The research and development carried out by all partners during the first year of the DIAdvisor programme brings this worthwhile goal one step closer.”

“Our increasingly sedentary lifestyles and unhealthy dietary habits have led to the incidence of diabetes approaching epidemic proportions,” Professor Christofer Toumazou, chairman of Toumaz Holdings, added. “Our Sensium technology is proving core in the deployment of a commercial solution to produce a successful personal continuous predictable monitor that will help transform the lives for diabetes sufferers. In addition, our collaborative and working relationships with leaders in the diabetes treatment market such as Novo Nordisk, will enable Toumaz Holdings to continue to build its presence in this expanding market.”